NCT00532428已完成4 期
Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- To determine the histomorphometric effects on bone,by iliac crest bone biopsy, of long-term (7 &8 yrs) therapy with raloxifene or placebo in postmenopausal women with osteoporosis who were enrolled in the CORE trial
研究概览
简要总结
This is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista Study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Have completed the CORE protocol within 3 months (90 days) prior to study entry and enrollment.
- •Have taken randomized study material for at least 7 years since enrollment in the MORE protocol. If the patient opted not to receive randomized study material for a period of 6 months at any point during either the MORE or CORE protocol, this period must have occurred in its entirety before Visit 3 of the CORE protocol.
- •Overall, were at least 75% compliant with randomized study material during the MORE and CORE protocols.
排除标准
- •Have an allergy or other intolerance to tetracycline hydrochloride that would preclude its administration in conjunction with the bone biopsy procedures. If the patient is not allergic to all tetracyclines, then this exclusion may be waived by the sponsor and a different tetracycline to which the patient is not allergic may be used.
- •Have undergone two previous transiliac bone biopsies (one in each iliac crest). Patients with one previous transiliac bone biopsy are eligible provided that the new sample is obtained from the contralateral iliac crest.
- •In the opinion of the investigator, have any medical or anatomical condition that potentially could put the patient at additional risk of an adverse event due to the procedure (for example, coagulation abnormality, extreme obesity, etc.).
- •Have a history of bone metabolic diseases, Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption.
- •Have a history of malignant neoplasms in the prior 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. If malignant neoplasm was ever diagnosed, patient must presently be free of disease.
研究组 & 干预措施
1
Active Comparator
干预措施: Raloxifene (Drug)
2
Active Comparator
干预措施: Raloxifene (Drug)
3
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
To determine the histomorphometric effects on bone,by iliac crest bone biopsy, of long-term (7 &8 yrs) therapy with raloxifene or placebo in postmenopausal women with osteoporosis who were enrolled in the CORE trial
时间窗: 6 months
次要结局
- Find effect of long-term treatment with raloxifene or placebo on bone quality. Primary measures: primary mineralization defect absence, mean degree of mineralization of bone tissue, absence of woven bone, microCT, microcrack & nanoindentation analysis.(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effect of raloxifene on bone metabolism, lipid profile and glucose metabolism in postmenopausal women with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000004399niversity of Occupational and Environmental Health, Japan150
已完成
4 期
Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid TherapyOsteoporosisNCT00371956Tuen Mun Hospital114
已完成
3 期
Effects of Arzoxifene on Bone Mass and the UterusPostmenopausal Bone LossNCT00085956Eli Lilly and Company300
已完成
3 期
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)Osteoporosis, PostmenopausalNCT00389740Organon and Co400
已完成
3 期
Effects of Arzoxifene on Bone Fractures and Incidence of Breast CancerOsteoporosis, PostmenopausalNCT00088010Eli Lilly and Company9,369